9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
220 articles with GlycoMimetics, Inc.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT.
Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc.
GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites
Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment
New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows
Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia
Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia (AML) patients eligible for intensive chemotherapy
GlycoMimetics, Inc. announced that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference.
GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
Third of three planned trials positions GlycoMimetics to address unmet needs across the AML spectrum
GlycoMimetics, Inc. reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.
GlycoMimetics, Inc. announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.
GlycoMimetics, Inc. announced that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia (AML), metastasis in osteosarcoma and other cancers will be shared via poster presentations at the AACR Annual Meeting 2018 in Chicago.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March
The Phase 3 trial of rivipansel remains on track for completion during the second half of 2018.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC (Mitoxantrone, etoposide and Ara-C) or in combination with FAI (fludarabine, cytosine arabinoside and idarubicin) in individuals with relapsed/refractory acute myeloid leukemia (AML).